With Wegovy and Ozempic's success, can device makers keep up in the race to treat obesity?

For the companies developing surgical tools and gastric balloons to treat obesity, new drugs like Wegovy and Ozempic present both a rich opportunity to capitalize on new interest in the condition and an existential threat to device makers' market share. Read more.

By Lizzy Lawrence

Courtesy Pat Furlong

For Duchenne moms who pushed for cures, new breakthrough therapy can't rebuild what's lost

For Pat Furlong (above) and an entire generation of parents, the approval of Sarepta's gene therapy, Elevidys, is an ecstatic moment, but one laced with pain. Their sons participated in study after study, establishing foundational knowledge both Sarepta and regulators relied on. Yet largely, those sons will not benefit. Some, like Furlong's, have died. Read more.

By Jason Mast

Kiera Hight for STAT

'I felt like I was dying': How women with postpartum depression fall through the cracks of U.S. health care

Five and a half months after Kristina Dulaney (above) had her second daughter, she developed postpartum psychosis. Navigating a health care system unprepared to support maternal mental health in the time surrounding the birth of a child is, unfortunately, far from a unique experience. Read more.

By Katharine Gammon

More great reads from STAT this week

The cancer drug shortage isn't new — and neither are the solutions: 'It's like Groundhog Day'
Walensky prepares to leave CDC — and Congress — after a bruising 29 months
After late start, Eli Lilly has the momentum in battle for $30 billion weight loss market
For volunteers at an eating disorder hotline, being replaced by an AI chatbot carried a painful cost
Global controversy heats up the race to build human embryo models from stem cells
Evangelist for legalizing MDMA therapy wrestles with his ideals as psychedelics go pharma
Opinion: The love my daughter and I found in the PICU